Search results
...Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology...
Morningstar· 5 days agoNuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of < ...
Phase III trial shows lorlatinib highly effective against ALK-positive non–small cell lung cancer
Medical Xpress· 2 days agoA large team of medical researchers and doctors has found via phase III clinical trial that the ALK inhibitor lorlatinib is highly effective for treating non–small cell lung cancer (NSCLC).
How to Cope With the Financial Toll of Cancer
Time via Yahoo Finance· 3 days agoIn fact, two years after a diagnosis, adults with cancer are 71% more likely to experience financial problems than those without a cancer diagnosis,...
Researchers complete first trial of Black patients with early-stage breast cancer
Medical Xpress· 2 days agoResults were presented today at the 2024 Annual Meeting of the American Society of Clinical Oncology...
Pfizer drug extends life for patients with rare lung cancer usually seen in nonsmokers
NBC Universal via AOL· 6 days agoPfizer’s lung cancer drug Lorbrena can extend life for patients with a rare form of the disease for...
Strong trial results for Pfizer lung cancer drug
Medical Xpress· 6 days agoA Pfizer medicine has been shown to greatly reduce cancer progression and improve survival outcomes for people in the advanced stages of a form of lung...
Docetaxel Tied to Less Taxane Neuropathy in Black Breast Cancer Patients
MedPage Today· 24 hours agoGermline variations did not predict the risk of taxane-induced peripheral neuropathy (TIPN) in a...
Pfizer's LORBRENA shows sustained NSCLC patient benefit over five years By Investing.com
Investing.com· 5 days agoThe findings, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and...
Opinion | What America owes long covid patients
Washington Post· 1 day agoBravo to The Post for the May 29 front-page article “For people of color with long covid, a ‘huge disparity.’” For too long, the long covid experiences...
New Lung Cancer Drug Trial Hailed As Best Result Ever, Setting A “New Benchmark”
IFLScience· 3 days agoPhase III trial results for a new drug targeting advanced lung cancer have just been reported, with...
